Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy - Lung Cancer
Afatinib/Cetuximab in EGFR TKI-Resistant NSCLC
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort - Journal of Thoracic Oncology
Frontiers | Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors | Oncology
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer | European Respiratory Society
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
![Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram](https://www.researchgate.net/publication/328978288/figure/fig2/AS:693427310178304@1542337362022/Mechanisms-of-acquired-resistance-to-osimertinib-32-36-EGFR-epidermal-growth-factor.png "Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram")
Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram
c-MET amplification upregulated PD-L1 expression in EGFR-TKI resistant... | Download Scientific Diagram
11 Terapias dirigidas Cáncer de Pulmón
Does c-Met remain a rational target for therapy in patients with EGFR TKI- resistant non-small cell lung cancer? - Cancer Treatment Reviews
Cells | Free Full-Text | Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy | HTML
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Figure 2 from Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. | Semantic Scholar
Diagnostics of EGFR-mutant disease: biomarkers with significant clinical implications - memoinOncology
PDF) MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer
Overview of probable resistance mechanisms in EGFR-TKI afatinib.... | Download Scientific Diagram
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
HER3 and mutant EGFR meet MET | Nature Medicine
Resistance mechanisms to osimertinib in EGFR -mutated non-small cell lung cancer | British Journal of Cancer
HCC827 GR cells are resistant to gefitinib in vitro and show MET... | Download Scientific Diagram
Resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer and strategies to overcome it | Australian Medical Student Journal
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer | Molecular Cancer Therapeutics
